Serum drug levels and anti-drug antibodies in the context of dose tapering by interval prolongation of adalimumab, etanercept and ustekinumab in psoriasis patients: results of the CONDOR trial

Background Biologics for psoriasis are registered in standard dosages. In patients with low disease activity, reduction of the dose by interval prolongation can prevent overtreatment, and lower risks and costs. However, fear for increased anti-drug antibody (ADA) formation due to interval prolongati...

Full description

Bibliographic Details

Published in:	Journal of Dermatological Treatment
Main Authors:	Selma Atalay, Sophie E. Berends, Hans M. M. Groenewoud, Ron A. A. Mathot, David M. Njoo, Johannes M. Mommers, Paul M. Ossenkoppele, Marjolein I. A. Koetsier, Maartje A. Berends, Annick de Vries, Peter C. M. van de Kerkhof, Alfons A. den Broeder, Elke M. G. J. de Jong, Juul M. P. A. van den Reek
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2022-07-01
Subjects:	Psoriasis adalimumab etanercept ustekinumab dose reduction dose tapering
Online Access:	https://www.tandfonline.com/doi/10.1080/09546634.2022.2043546